Dyax Corp. (NASDAQ: DYAX) is focused on discovering, developing, and commercializing novel biopharmaceuticals for medical needs that are currently unmet. The company hopes to meet its objectives while delivering outstanding value to patients and stockholders. Their produce candidates include fully human monoclonal antibodies in addition to small proteins and peptides. For further information, visit the Company’s web site at www.dyax.com.
- 18 years ago
QualityStocks
Dyax Corp. (NASDAQ: DYAX)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…